Pharmaceutical giant Merck & Co.’s Austrian subsidiary is challenging #CancerCalculus journalists’ efforts to obtain pricing data in a case likely to test the limits of the country’s freedom of information law, which was enacted in Sept. 2025.
Merck takes Austria’s Keytruda price transparency battle to top court as journalists fight for information - ICIJ
The case stems from ICIJ’s Cancer Calculus investigation into the world's best-selling drug’s sky-high price and its global consequences.
buff.ly
